Skip to main content
Fig. 10 | BMC Cancer

Fig. 10

From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma

Fig. 10

MS-275 treatment reduced clonogenic potential of NB and teratocarcinoma cells. a clonogenic potential was negatively affected with increasing doses of MS-275. b dose response curves of MS-275 treatment of NT2/D1, SH-SY5Y and SK-N-BE(2) over a 2 week growth period in methycellulose compared to control. Similarly, clonogenic capacity was negatively affected in all three cell lines despite different initial clonogenic efficiencies. IC50 values were calculated to be 0.13 μM, 0.20 μM and 0.18 μM for NT2/D1, SH-SY5Y and SK-N-BE(2), respectively. c representative images for control, 0.2 μM and 0.75 μM MS-275 treatments in methycellulose clonogenic assay run on NT2/D1 and SK-N-BE(2)

Back to article page